The global Protein Therapeutics Market is undergoing a transformative growth phase, driven by rapid advancements in biotechnology, rising prevalence of chronic diseases, and a strong shift toward targeted, personalized medicine solutions. Valued at US$ 318.4 Bn in 2022, the market is projected to expand at a CAGR of 6.3% from 2023 to 2031, reaching over US$ 549.4 Bn by 2031.

Rising Burden of Chronic Diseases Strengthens Market Demand

The global incidence of cancer, diabetes, metabolic disorders, and autoimmune diseases continues to escalate, reinforcing the need for precision-oriented biologic therapies. Protein therapeutics — especially monoclonal antibodies (mAbs) — have become central to modern treatment strategies.

mAbs, engineered to specifically target disease-related antigens, have reshaped treatment pathways for oncology, autoimmune disorders, and hematological diseases. Their ability to precisely modulate immune responses and attack malignant cells while sparing healthy tissues has significantly improved patient outcomes and survival rates.

As chronic disease prevalence grows worldwide, the market for protein-based therapies continues to rise in tandem.

Biosimilars Surge Creates New Growth Opportunities

One of the most significant growth drivers in recent years is the expiration of patents for leading biologics, paving the way for a robust biosimilar landscape.

Biosimilars offer:

• Comparable efficacy and safety to reference biologics

• Lower treatment costs

• Increased accessibility for large patient pools

• Greater market competition

With streamlined regulatory pathways and growing acceptance across healthcare systems, biosimilars are expected to play a major role in reshaping global protein therapeutics demand over the next decade.

Monoclonal Antibodies Lead Market Segmentation

Among all product categories, monoclonal antibodies dominated the market in 2022, owing to:

• Their expanding role in cancer immunotherapy

• Increasing adoption across metabolic and immunologic disorders

• Breakthroughs in bispecific and next-generation antibody engineering

Other key therapeutic protein categories — including enzyme replacement therapies, cytokines, BMPs, hormones, anti-coagulants, fusion proteins, and engineered scaffolds — remain essential pillars supporting market diversification.

Cancer Remains the Leading Application Area

The cancer segment accounted for the largest market share in 2022 due to widespread adoption of:

• Immune checkpoint inhibitors

• Antibody-drug conjugates (ADCs)

• Targeted mAbs

These innovations are transforming oncology care by enabling personalized and molecularly precise treatment regimens.

North America Leads, Asia Pacific Accelerates

North America

• Strong biotech ecosystem

• High R&D investments

• Presence of major biopharmaceutical companies

• Favorable FDA regulatory pathways

The U.S. remains the global powerhouse for protein therapeutics innovation and commercialization.

Asia Pacific

• Rapid healthcare infrastructure upgrades

• Large and diverse patient base

• Growing incidence of chronic diseases

• Expanding biopharmaceutical manufacturing capacity

China, India, Japan, and South Korea are positioned as high-growth hubs through 2031.

Competitive Landscape: Innovation & Collaboration Dominate

The market is fragmented yet highly competitive, with major players including:
Thermo Fisher Scientific, Sanofi/Genzyme, AbbVie, Takeda, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Abbott, Leadiant Biosciences, Amicus Therapeutics.

Key strategic moves include:

• Thermo Fisher acquiring PeproTech (2022) to strengthen recombinant protein capabilities

• Plexium–AbbVie partnership (2022) to advance targeted protein degradation (TPD) in neurological diseases

Industry players continue to invest heavily in R&D, personalized medicine platforms, and strategic alliances to maintain leadership.